Research Comparison
KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV) vs TB-500
A side-by-side research comparison of KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV) and TB-500 drawn from Cobalt Peptides' peptide database records.
KLOW Stack (GHK-Cu + TB-500 + BPC-157 + KPV)
The KLOW Protocol is a four-peptide regenerative blend combining GHK-Cu, TB-500 (Thymosin Beta-4), BPC-157, and KPV. It builds upon the GLOW protocol by incorporating KPV, a tripeptide with anti-inflammatory activity, to enhance tolerability and broaden mechanistic coverage. Typical formulations contain approximately 50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, and 10mg KPV in a 5:1:1:1 ratio. While individual peptides have established research backgrounds, no clinical trials have evaluated this specific combination, and all effects remain theoretical based on additive and complementary mechanisms.
TB-500
TB-500 is a synthetic 7-amino acid fragment (Ac-LKKTETQ) corresponding to the active actin-binding region (positions 17-23) of thymosin beta-4. Originally developed for veterinary use, this fragment retains tissue repair and anti-inflammatory properties while being more stable than the full peptide. TB-500 regulates actin dynamics, promotes cell migration, enhances angiogenesis, and reduces inflammation, contributing to accelerated tissue repair across multiple systems. Its systemic distribution enables whole-body regenerative support rather than localized effects alone.